Abeona Therapeutics(NASDAQ) ABEO

Abeona Therapeutics makes gene therapies for people with rare diseases. Its main product helps heal painful skin wounds. The company builds these treatments in its own Ohio factory.

Treating Rare Genetic Diseases

• ZEVASKYN: Autologous cell-based gene therapy that uses a patient's own cells to treat skin wounds; accounted for 100% of total revenue in the six-month period ended June 30, 2026.
• ABO-701: Investigational T-cell therapy candidate designed to target and treat solid tumors.
• AIM Vector Platform: Proprietary technology used to develop adeno-associated virus gene therapies for various genetic disorders.

Expansion and Strategic Deals

• Activated Cincinnati Children's as the seventh qualified treatment center for ZEVASKYN on July 21, 2026.
• Entered a license and joint development agreement for the ABO-701 program in March 2026 with a $7 million upfront payment.
• Sold a priority review voucher in May 2025 for gross proceeds of $155 million following FDA approval of its lead product.
• Recorded the first commercial sale of ZEVASKYN in Dec. 2025.

Specialized Manufacturing Strength

Abeona maintains a fully integrated cell and gene therapy manufacturing facility in Cleveland, Ohio. This internal facility serves as the primary site for both commercial production and clinical trial material development.

Vital Signs and Key Figures

• Total revenues were $11.4 million for the three months ended June 30, 2026, up 2,745% year over year.
• Net loss was $20.2 million for the three-month period ended June 30, 2026, compared to a net income of $108.8 million in the same period of 2025.
• Cash, cash equivalents, and short-term investments totaled $146.8 million as of June 30, 2026.
• Research and development expenses were $5.0 million for the quarter ended June 30, 2026, a decrease of 16% year over year.
• Product revenue from ZEVASKYN sales reached $20.1 million for the six-month period ended June 30, 2026.

The Next Chapter

Abeona has transitioned from a clinical-stage developer to a commercial-stage company following the 2025 launch of its first gene therapy. Its focus on specialized internal manufacturing and rare disease treatments defines its current operational strategy.